PARIS, June 16 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), announced today the first edition of The Genome Customization Award, for academic research teams across the world who are undertaking targeted modification of the genome of a cell line or that of a model organism using one or more meganucleases provided by Cellectis bioresearch.
"Through this award, Cellectis bioresearch aims at spreading the use of meganucleases for genome customization, throughout the Life Sciences community," explained Marc Le Bozec, CEO of Cellectis bioresearch. Priority will be given to innovative projects allowing a technological breakthrough.
The winning academic team will receive 15,000 euro (US$18,000) to partially fund one postdoctoral fellow recruited to work on the project, for one year, with a possible renewal for a second year.
The deadline for submitting applications is October 1, 2010. The winner will be announced on December 15, 2010, by a selection committee composed of respected genetic experts at some of the most well regarded academic institutions including:
For full program detail or to apply, go to http://www.cellectis-bioresearch.com/award/.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional study.
More information at www.cellectis-bioresearch.com
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over 70 million euro in funding since inception.
More information at www.cellectis.com
Follow us on Twitter at www.twitter.com/cellectis
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
|SOURCE Cellectis bioresearch|
Copyright©2010 PR Newswire.
All rights reserved